304 related articles for article (PubMed ID: 33886338)
1. Enhanced Antitumor Immune Responses via a Self-Assembled Carrier-Free Nanovaccine.
Liu D; Deng B; Liu Z; Ma B; Leng X; Kong D; Ji T; Liu L
Nano Lett; 2021 May; 21(9):3965-3973. PubMed ID: 33886338
[TBL] [Abstract][Full Text] [Related]
2. Antigen epitope-TLR7/8a conjugate as self-assembled carrier-free nanovaccine for personalized immunotherapy.
Song H; Su Q; Shi W; Huang P; Zhang C; Zhang C; Liu Q; Wang W
Acta Biomater; 2022 Mar; 141():398-407. PubMed ID: 35007785
[TBL] [Abstract][Full Text] [Related]
3. A Visible Codelivery Nanovaccine of Antigen and Adjuvant with Self-Carrier for Cancer Immunotherapy.
Dong X; Liang J; Yang A; Qian Z; Kong D; Lv F
ACS Appl Mater Interfaces; 2019 Feb; 11(5):4876-4888. PubMed ID: 30628437
[TBL] [Abstract][Full Text] [Related]
4. CpG-Based Nanovaccines for Cancer Immunotherapy.
Chen W; Jiang M; Yu W; Xu Z; Liu X; Jia Q; Guan X; Zhang W
Int J Nanomedicine; 2021; 16():5281-5299. PubMed ID: 34385817
[TBL] [Abstract][Full Text] [Related]
5. Mannan-decorated pathogen-like polymeric nanoparticles as nanovaccine carriers for eliciting superior anticancer immunity.
Xu Y; Ma S; Zhao J; Chen H; Si X; Huang Z; Yu Z; Song W; Tang Z; Chen X
Biomaterials; 2022 May; 284():121489. PubMed ID: 35364489
[TBL] [Abstract][Full Text] [Related]
6. RNA Origami Functions as a Self-Adjuvanted Nanovaccine Platform for Cancer Immunotherapy.
Yip T; Qi X; Yan H; Chang Y
ACS Nano; 2024 Feb; 18(5):4056-4067. PubMed ID: 38270089
[TBL] [Abstract][Full Text] [Related]
7. Carrier-free subunit nanovaccine amplifies immune responses against tumors and viral infections.
Chen H; Li Y; Li L; Yang Z; Wen Z; Liu L; Liu H; Chen Y
Acta Biomater; 2023 Mar; 158():525-534. PubMed ID: 36572250
[TBL] [Abstract][Full Text] [Related]
8. Cooperating minimalist nanovaccine with PD-1 blockade for effective and feasible cancer immunotherapy.
Jiang M; Zhao L; Cui X; Wu X; Zhang Y; Guan X; Ma J; Zhang W
J Adv Res; 2022 Jan; 35():49-60. PubMed ID: 35003793
[TBL] [Abstract][Full Text] [Related]
9. Facile preparation of a metal-phenolic network-based lymph node targeting nanovaccine for antitumor immunotherapy.
Su Q; Liu Z; Du R; Chen X; Chen L; Fu Z; Luo X; Yang Y; Shi X
Acta Biomater; 2023 Mar; 158():510-524. PubMed ID: 36603733
[TBL] [Abstract][Full Text] [Related]
10. Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response.
Zhang L; Huang J; Chen X; Pan C; He Y; Su R; Guo D; Yin S; Wang S; Zhou L; Chen J; Zheng S; Qiao Y
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34452929
[TBL] [Abstract][Full Text] [Related]
11. Rational incorporation of molecular adjuvants into a hybrid nanoparticle-based nicotine vaccine for immunotherapy against nicotine addiction.
Zhao Z; Harris B; Hu Y; Harmon T; Pentel PR; Ehrich M; Zhang C
Biomaterials; 2018 Feb; 155():165-175. PubMed ID: 29179132
[TBL] [Abstract][Full Text] [Related]
12. Vaccination of TLR7/8 Agonist-Conjugated Antigen Nanoparticles for Cancer Immunotherapy.
Wang N; Zhang G; Zhang P; Zhao K; Tian Y; Cui J
Adv Healthc Mater; 2023 Sep; 12(22):e2300249. PubMed ID: 37016572
[TBL] [Abstract][Full Text] [Related]
13. Monophosphoryl lipid A-assembled nanovaccines enhance tumor immunotherapy.
Li R; Hao Y; Pan W; Wang W; Min Y
Acta Biomater; 2023 Nov; 171():482-494. PubMed ID: 37708924
[TBL] [Abstract][Full Text] [Related]
14. In Situ Cocktail Nanovaccine for Cancer Immunotherapy.
Liu M; Xie D; Hu D; Zhang R; Wang Y; Tang L; Zhou B; Zhao B; Yang L
Adv Sci (Weinh); 2023 Nov; 10(31):e2207697. PubMed ID: 37740439
[TBL] [Abstract][Full Text] [Related]
15. Co-assembled nanocomplexes of peptide neoantigen Adpgk and Toll-like receptor 9 agonist CpG ODN for efficient colorectal cancer immunotherapy.
Liang Z; Cui X; Yang L; Hu Q; Li D; Zhang X; Han L; Shi S; Shen Y; Zhao W; Ju Q; Deng X; Wu Y; Sheng W
Int J Pharm; 2021 Oct; 608():121091. PubMed ID: 34555477
[TBL] [Abstract][Full Text] [Related]
16. Construction of pH-Sensitive Nanovaccines Encapsulating Tumor Cell Lysates and Immune Adjuvants for Breast Cancer Therapy.
Ding Y; Yang J; Wei H; Wang J; Huang S; Yang S; Guo Y; Li B; Shuai X
Small; 2023 Sep; 19(37):e2301420. PubMed ID: 37154213
[TBL] [Abstract][Full Text] [Related]
17. Minimalist Nanovaccine with Optimized Amphiphilic Copolymers for Cancer Immunotherapy.
Niu L; Miao Y; Cao Z; Wei T; Zhu J; Li M; Bai B; Chen L; Liu N; Pan F; Zhu J; Wang C; Yang Y; Chen Q
ACS Nano; 2024 Jan; 18(4):3349-3361. PubMed ID: 38230639
[TBL] [Abstract][Full Text] [Related]
18. Liposomes-coated gold nanocages with antigens and adjuvants targeted delivery to dendritic cells for enhancing antitumor immune response.
Liang R; Xie J; Li J; Wang K; Liu L; Gao Y; Hussain M; Shen G; Zhu J; Tao J
Biomaterials; 2017 Dec; 149():41-50. PubMed ID: 28992509
[TBL] [Abstract][Full Text] [Related]
19. RNA cancer vaccines: developing mRNA nanovaccine with self-adjuvant property for cancer immunotherapy.
Zhang H; Xia X
Hum Vaccin Immunother; 2021 Sep; 17(9):2995-2998. PubMed ID: 33945399
[TBL] [Abstract][Full Text] [Related]
20. A generally minimalist strategy of constructing biomineralized high-efficiency personalized nanovaccine combined with immune checkpoint blockade for cancer immunotherapy.
Zhang S; Feng Y; Meng M; Li Z; Li H; Lin L; Xu C; Chen J; Hao K; Tang Z; Tian H; Chen X
Biomaterials; 2022 Oct; 289():121794. PubMed ID: 36113330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]